Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting

About this update from Protagonist Therapeutics, Inc.

[{"type":"text","content":"NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematology (ASH) annual meeting, taking place in a virtual format December 5-8, 2020. The abstract data includes results as of early August 2020 from the ongoing Phase 2 study of PTG-300 in the treatment of polycythemia vera. Additional updated data from the study will be available during presentations at the conference.\n\"This year's ASH meeting provides an opportunity for Protagonist to share detailed findings of its PTG-300 hepcidin mimetic program for polycythemia vera (PV) at a major medical conference for the first time,\" commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. \"We look forward to presenting updated results from our ongoing Phase 2 PTG-300 proof-of-concept PV study at the conference. We will also present an analysis of real world patient data and potential unmet need in PV, as well as promising preclinical findings with a new oral hepcidin mimetic peptide. As a non-cytoreductive treatment option based on the activity of a natural hormone, PTG-300 has truly transformative potential for PV patients and we look forward to advancing PTG-300 on the path toward regulatory approval as efficiently as possible.\" \nOral presentation:\n1) Title: PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients (Abstract #482)Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials in Polycythemia Vera Session Date: Sunday, December 6, 2020 Presentation Time: 2:45 p.m. PSTPresenter: Marina Kremyanskaya, M.D., Ph.D., Icahn School of Medicine at Mount Sinai\nPoster presentations:\n2) Title: Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients (Abstract #1689)Session: 102. Regulation of Iron Metabolism: Poster II Date: Sunday, December 6, 2020Presenter: Yelena Ginzburg, M.D., Icahn School of Medicine at Mount Sinai\n3) Title: Real-World Treatments and Thrombotic Events in Polycythemia Vera Patients: A Retrospective Analysis between 2018-2019 in US Population (Abstract #2998)Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III Date: Monday, December 7, 2020Prese...

More updates from Protagonist Therapeutics, Inc.